IMATINIB AMOMED õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

imatinib amomed õhukese polümeerikattega tablett

amomed pharma gmbh - imatiniib - õhukese polümeerikattega tablett - 100mg 180tk; 100mg 120tk; 100mg 60tk

REMERON SOLTAB suus dispergeeruv tablett Eesti - eesti - Ravimiamet

remeron soltab suus dispergeeruv tablett

organon n.v. - mirtasapiin - suus dispergeeruv tablett - 30mg 30tk

REMERON SOLTAB suus dispergeeruv tablett Eesti - eesti - Ravimiamet

remeron soltab suus dispergeeruv tablett

organon n.v. - mirtasapiin - suus dispergeeruv tablett - 15mg 30tk; 15mg 48tk

REMERGIL SOLTAB suus dispergeeruv tablett Eesti - eesti - Ravimiamet

remergil soltab suus dispergeeruv tablett

merc sharp & dohme s.p.a - mirtasapiin - suus dispergeeruv tablett - 30mg 48tk

REMERON SOLTAB dispergeeruv tablett Eesti - eesti - Ravimiamet

remeron soltab dispergeeruv tablett

organon n.v. - mirtasapiin - dispergeeruv tablett - 30mg 48tk

Thiotepa Riemser Euroopa Liit - eesti - EMA (European Medicines Agency)

thiotepa riemser

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastilised ained - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Plerixafor Accord Euroopa Liit - eesti - EMA (European Medicines Agency)

plerixafor accord

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Ebvallo Euroopa Liit - eesti - EMA (European Medicines Agency)

ebvallo

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Aubagio Euroopa Liit - eesti - EMA (European Medicines Agency)

aubagio

sanofi winthrop industrie - teriflunomide - hulgiskleroos - selektiivsed immunosupressandid - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Cuprymina Euroopa Liit - eesti - EMA (European Medicines Agency)

cuprymina

a.c.o.m. - advanced center oncology - vask (64cu) kloriid - radionukliidi pildistamine - various diagnostic radiopharmaceuticals - cuprymina on radiofarmatseutiline prekursor. see ei ole mõeldud otseselt kasutamiseks patsientidel. seda ravimit tohib kasutada ainult radioaktiivse märgistamise jaoks kandemolekulidel, mis on spetsiaalselt välja töötatud ja rajatist märgistatud selle radionukliidiga.